• See Us At
    July 21, 2026

    Join Sanket Anshuman, Practice Director at Everest Group, to explore how pharmacovigilance (PV) is evolving from a compliance-driven function to an AI-enabled, intelligence-led safety model. Discover how organizations can leverage AI, automation, and real-world data to…
  • Blog
    July 08, 2026

    Artificial Intelligence (AI) is having its moment. After years of cautious skepticism, pilot-stage overhang, and boardroom debates, the conversation has moved beyond experimentation. Enterprises are no longer asking whether to deploy agents, they are now asking how fast they can scale them across their entire workflow estate. However, speed comes at a price and almost nobody is doing the math.   The warning signs…
  • Viewpoint
    June 29, 2026

    The post-approval phase represents one of the most complex and strategically critical stages in the life sciences product life cycle, requiring enterprises to ensure continuous safety monitoring, regulatory compliance, and real-world performance optimization. With increasing diverse…
  • Thematic Report
    May 04, 2026

    The global Clinical Research Organization (CRO) market is undergoing a transformation, shaped by rising clinical trial complexity, increasing regulatory requirements, and growing demand for faster, more efficient drug development. CROs continue to play a pivotal role…
  • Viewpoint
    April 28, 2026

    The global safety database market is at an inflection point, driven by increasing complexities in Pharmacovigilance (PV) operations, growing regulatory expectations, and rapid expansion of data sources such as real-world evidence, digital health tools, and patient-generated…
  • Roundtable
    April 16, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Thursday, May 07, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Roundtable
    March 31, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Tuesday, April 14, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Provider Compendium
    Dec. 30, 2025

    Enterprises are repositioning quality from a downstream testing activity to a strategic engineering capability embedded across the software development life cycle. As digital, cloud, and AI initiatives scale, expectations are moving beyond defect identification toward resilience,…
  • LinkedIn Live
    Nov. 19, 2025

    In an evolving landscape where analyst relations (AR) shape market perception and business success, leaders continued to look for proven tactics embraced by experienced AR professionals. Everest Group’s Katrina Menzigian, along with industry experts from other…
  • PEAK Matrix®
    Nov. 13, 2025

    Enterprises are elevating quality from a downstream test phase to a strategic engineering discipline woven through the software development life cycle. As digital, cloud, and AI programs scale, expectations shift from defect detection to resilience, velocity,…
  • Viewpoint
    Nov. 10, 2025

    As enterprises accelerate digital transformation and embrace next-generation technologies such as AI, generative AI, and cloud-native platforms, managing quality at scale has become increasingly complex. Traditional tool-centric quality approaches fall short in addressing fragmented processes, inconsistent…
  • Market Insights™
    Nov. 05, 2025

  • In 2006, I visited my first captive center in Bengaluru. At the time, the model was still in its formative years – many multinational organizations were only beginning to explore the potential of setting up their own in-house centers…
  • Blog
    Nov. 02, 2025

    The clinical outsourcing market is undergoing a transition with the emergence of specialist-focused Clinical Research Organizations (CROs). A specialist CRO concentrates its expertise in a defined area, such as a therapeutic focus, trial phase or technology, or geographic niche, rather than offering broad,…
  • PEAK Matrix®
    Oct. 29, 2025

    Enterprises are reimagining quality as a strategic engineering function rather than a downstream testing activity. As a result, demand for specialized Quality Engineering (QE) services is growing rapidly across industries. This analysis shows how the specialists…
  • State of the Market
    Oct. 01, 2025

    The surge in case volumes, more stringent regulatory demands, and therapeutic areas’ rising complexities are significantly transforming pharmacovigilance (PV). As the industry adapts to more tailored reporting requirements and longer patient monitoring periods, enterprises are under…
  • Provider Compendium
    Sep. 30, 2025

    In recent years, life sciences enterprises have reoriented their R&D investments, prioritizing pipeline efficiency and a strategic focus on large and novel molecules. This shift has intensified efforts around cost containment and created a stronger need…
  • Provider Compendium
    Sep. 16, 2025

    Pharmacovigilance (PV) operations have become a strategic priority for life sciences enterprises facing heightened regulatory scrutiny, evolving safety standards, and growing complexity across global markets. This report provides an in-depth assessment of 12 leading PV service…
  • Webinar Deck
    July 31, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • Event
    July 29, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…

Items per page